EUCTR2004-004499-35-CZ进行中（未招募）不适用
A Study to Evaluate the Efficacy of Converting from Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa in Subjects with Chronic Kidney Disease Receiving Haemodialysis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Treatment Period 1:
- •1. Diagnosis of CKD and receiving dialysis for at least 3 months prior to screening
- •2. = 18 years of age
- •3. Baseline Hb level = 10.0 g/dL and = 13.0 g/dL
- •4. Adequate iron stores (defined as serum ferritin =100 µg/L or transferrin saturation (TSAT) = 20%)
- •5. Stable IV (Epoetin alfa or beta) or SC rHuEPO (Epoetin beta) therapy 1, 2, or 3 times per week for at least 8 weeks before screening (stable is defined as < 25% change in weekly dose and no change in frequency or route)
- •6. Before any study-specific procedure, the appropriate written informed consent must be obtained (see Section 12.1).
- •Treatment Period 2:
- •1. Completed Treatment Period 1.
- •2. Hb > 11.0 g/dL and = 13.0 g/dL at week 24
- •3. Stable QW dose of IV darbepoetin alfa during Evaluation Period 1 (weeks 21 to 24). A stable dose is defined as:
- •a. no prescribed dose increases, prescribed dose reductions or withheld doses
- •b. no more than 1 missed dose
- •c. no changes to dose frequency or route of administration
- •4. Before any protocol specific procedure for Treatment Period 2 is performed, the appropriate written informed consent must be obtained (see Section 12.1)
- •5. Adequate iron stores (defined as serum ferritin = 100 µg/L or TSAT = 20%) at week 24
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Treatment Period 1:
- •1. Received SC Epoetin alpha in the 12 months before screening
- •2. Uncontrolled hypertension (diastolic blood pressure > 100 mm Hg)
- •3. Prior history (within 12 weeks before enrolment) of cardiovascular events including:
- •- acute myocardial ischemia
- •- hospitalization for congestive heart failure
- •- myocardial infarction
- •· Pregnant or breast-feeding women. All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial.
- •· Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study.
- •· Known sensitivity to any of the products to be administered during dosing.
- •· Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
- •Treatment Period 2:
- •1. Uncontrolled hypertension (diastolic blood pressure > 100 mmHg or systolic blood pressure > 180 mmHg) on 2 separate occasions during Evaluation Period 1 (weeks 21 to 24)
- •2. Received a red blood cell transfusion during study weeks 16 to 24
研究者
相似试验
进行中（未招募）
不适用
A Study to Evaluate the Efficacy of Converting from Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects with Chronic Kidney Disease Receiving HaemodialysisAnemia caused by chronic kidney didease.MedDRA version: 6.1Level: PTClassification code 10038444EUCTR2004-004499-35-HUAmgen Limited200
尚未招募
2 期
An experimental study to see the effectiveness of Modified early warning score on selected patient outcomes in emergency department of hospitalCTRI/2024/05/067765Dr Sujata Chaudhury Prof Head Department of Anaesthesia
进行中（未招募）
1 期
A prospective and randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation (REVERSE study) - REVERSEEUCTR2006-001765-42-BEZ Brussel110
进行中（未招募）
1 期
A prospective and randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation (REVERSE study) - REVERSEEUCTR2006-001765-42-DEB Erasme200
已完成
不适用
Excellence of the closed intensive care unit system in critically ill surgical patients: A retrospective cohort studyDiseases of the circulatory systemKCT0008099Ewha Womans University Medical Center900